Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors.

@article{Zurita2011CirculatingPA,
  title={Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors.},
  author={Amado J. Zurita and John V. Heymach and Mehrdad Khajavi and Lesley M. Tye and Xin Huang and Matthew H. Kulke and Heinz-Josef Lenz and Neal J. Meropol and William Carley and Samuel E Deprimo and Charles S. Harmon},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2011},
  volume={29 15_suppl},
  pages={4079}
}
4079 Background: Biomarkers of sunitinib malate (SU) therapy were characterized via analysis of levels of a panel of soluble proteins in plasma samples collected from pts with advanced carcinoid and pancreatic neuroendocrine tumor (NET) treated in a phase II trial. Changes in specific subsets of peripheral blood mononuclear cells (PBMC) and circulating endothelial/progenitor cells (CEC/CEP) expressing relevant targets were also examined. METHODS Pts with carcinoid or pancreatic NET were… CONTINUE READING